iSTAR Medical
Edit

iSTAR Medical

https://www.istarmed.com/
Last activity: 16.06.2022
Active
Categories: CauseClinicDevelopmentHardwareManagementMarketMedTechProductTechnologyUniversity
iSTAR Medical SA, headquartered in Wavre, Belgium, is a clinical stage medical technology company focused on the development of novel ophthalmic implants for glaucoma.

Glaucoma is the second leading cause of adult blindness globally. Micro-invasive glaucoma surgery (MIGS) is the most promising and fastest-growing therapeutic option in the treatment of glaucoma. iSTAR has exclusive rights to the STAR material from the University of Washington in Seattle (USA) for ophthalmic use. This provides the foundation for the development of MINIject, which is designed to be a best in class MIGS device. The fast-growing glaucoma drainage device market is expected to reach $1bn worldwide by 2020.

iSTAR Medical’s management team and board have a successful track record in end-to-end product development, with proven clinical, regulatory and market access capabilities. The company is backed by specialised institutional and private investors.
Followers
146
Followers
1.93K
Mentions
18
Location: Belgium, Walloon Brabant, Wavre
Employees: 11-50
Total raised: $61.02M
Founded date: 2010

Investors 9

Funding Rounds 3

DateSeriesAmountInvestors
05.09.2019Series C$44.23M-
12.04.2016Series B$11.39M-
21.11.2013Series A$5.4M-

Mentions in press and media 18

DateTitleDescription
15.07.2021iSTAR Medical receives US FDA approval to start pivotal trial for MINIject in glaucoma patientsWavre, Belgium: 15 July 2021 – iSTAR Medical, a med-tech company developing minimally-invasive implants for glaucoma surgery (MIGS), announced today that the U.S. Food and Drug Administration (FDA) granted it Investigational Device Exemptio...
15.07.2021iSTAR Medical receives U.S. FDA approval to start pivotal trial for MINIject in glaucoma patientsWAVRE, Belgium, July 15, 2021 /PRNewswire/ -- iSTAR Medical, a med-tech company developing minimally-invasive implants for glaucoma surgery (MIGS), announced today that the U.S. Food and Drug Administration (FDA) granted it Investigational ...
15.07.2021iSTAR Medical receives U.S. FDA approval to start pivotal trial for MINIject in glaucoma patients USA - English USA - English España - español France - Français Nederland - Nederlands Italia - Italia...
15.07.2021iSTAR Medical receives U.S. FDA approval to start pivotal trial for MINIject in glaucoma patients USA - English España - español France - Français Nederland - Nederlands Italia - Italiano USA - Engli...
16.11.2020iSTAR Medical’s glaucoma device MINIject shows positive one-year results in European trialWavre, Belgium: 16 November 2020 – iSTAR Medical, a medtech company developing minimally invasive ophthalmic implants for treatment of patients with glaucoma, today announced positive one-year results from the European STAR-II clinical tria...
29.09.2020Positive outcomes for iSTAR Medical’s MIGS MINIject shown in trials of over 130 glaucoma patientsPooled data confirm excellent safety and efficacy profile with very low rate of reintervention
29.04.2020iSTAR Medical announces outstanding results with MIGS implantTwo-year final results from STAR-I trial and initial data from STAR-II European trial tout MINIjectTM as a highly promising treatment.
06.12.2019Best of 2019: 10 Belgium tech startups that scored maximum funding this yearEntrepreneurs in Belgium eyeing to raise funds might have an easier time right now to grow their rice as the startup ecosystem in the country is heating up. Not only funding but also starting a business in Belgium does not take as much effo...
05.09.2019iSTAR Medical announces € 40 million Series C financingTo accelerate development and commercialisation of innovative Glaucoma MIGS device, MINIjectTM
05.09.2019iSTAR Medical Raises €40M in Series C FinancingiSTAR Medical SA, a Wavre, Belgium-based medical device company developing novel ophthalmic implants for the treatment of glaucoma, raised €40m in Series C financing. The round was led by LSP and Gimv, with participation from Earlybird and ...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In